Felix B Yap1. 1. Department of Medicine, Faculty of Medicine & Health Sciences, Universiti Tunku Abdul Rahman, Kajang, Selangor, Malaysia.
Abstract
OBJECTIVES: This study aimed to investigate the off-label use of a combination calcipotriol plus betamethasone dipropionate (CBD) gel in the treatment of moderate-to-severe scalp seborrhoeic dermatitis (SSD). METHODS: This retrospective study involved 32 patients with SSD who were prescribed CBD gel at the Subang Jaya Medical Centre, Selangor, Malaysia, between January 2016 and December 2017. The Physician Global Assessment Scale was used to assess disease severity. Itching/discomfort was evaluated using a visual analogue scale. RESULTS: The mean age was 35.8 ± 6.9 years. Severe disease was seen in 53.1%. Complete clearance was recorded in 15.6%, 40.6% and 59.4% of patients at weeks two, six and 10, respectively. By week 10, 87.5% had achieved marked improvement. Both mean itching and discomfort scores significantly improved at weeks two, six and 10 (P <0.001). Better outcomes were significantly associated with disease duration and itching intensity and discomfort at presentation (P <0.050). CONCLUSION: CBD gel should be considered as an option for SSD cases not adequately controlled by prior conventional treatment.
OBJECTIVES: This study aimed to investigate the off-label use of a combination calcipotriol plus betamethasone dipropionate (CBD) gel in the treatment of moderate-to-severe scalp seborrhoeic dermatitis (SSD). METHODS: This retrospective study involved 32 patients with SSD who were prescribed CBD gel at the Subang Jaya Medical Centre, Selangor, Malaysia, between January 2016 and December 2017. The Physician Global Assessment Scale was used to assess disease severity. Itching/discomfort was evaluated using a visual analogue scale. RESULTS: The mean age was 35.8 ± 6.9 years. Severe disease was seen in 53.1%. Complete clearance was recorded in 15.6%, 40.6% and 59.4% of patients at weeks two, six and 10, respectively. By week 10, 87.5% had achieved marked improvement. Both mean itching and discomfort scores significantly improved at weeks two, six and 10 (P <0.001). Better outcomes were significantly associated with disease duration and itching intensity and discomfort at presentation (P <0.050). CONCLUSION: CBD gel should be considered as an option for SSD cases not adequately controlled by prior conventional treatment.
Authors: J-P Ortonne; A F Nikkels; K Reich; R M Ponce Olivera; J H Lee; N Kerrouche; F Sidou; J Faergemann Journal: Br J Dermatol Date: 2011-07 Impact factor: 9.302
Authors: Massimo Milani; Sabino Antonio Di Molfetta; Raffaele Gramazio; Carmen Fiorella; Costantino Frisario; Ernesto Fuzio; Vincenzo Marzocca; Maria Zurilli; Giovanni Di Turi; Giovanni Felice Journal: Curr Med Res Opin Date: 2003 Impact factor: 2.580
Authors: P C M van de Kerkhof; V Hoffmann; A Anstey; L Barnes; C Bolduc; K Reich; S Saari; S Segaert; L Vaillant Journal: Br J Dermatol Date: 2008-11-25 Impact factor: 9.302
Authors: Helena Kastarinen; Tuija Oksanen; Enembe O Okokon; Vesa V Kiviniemi; Kristiina Airola; Johanna Jyrkkä; Tuomas Oravilahti; Piia K Rannanheimo; Jos H Verbeek Journal: Cochrane Database Syst Rev Date: 2014-05-19